Amesite Signs New 2,000-Patient NurseMagic® Enterprise Customer, Extending Growth Among Large Healthcare Organizations
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amesite (AMST) signed a new NurseMagic enterprise agreement with a healthcare organization serving approximately 2,000 patients, expanding its customer portfolio.
The contract increases revenue, users and patient census and extends Amesite into healthcare services for rural Medicare and Medicaid populations. Median customer census at signing increased 4x from 2025 to 2026. Amesite also reported shipping more than 13 times as much code each quarter as in the first quarter of 2025, including a 37% increase in the third quarter of 2026 over the second quarter, without adding engineers. The company says its existing AI infrastructure enables customer-specific capabilities to be deployed in days without replacing customers’ existing systems.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNew enterprise agreement with an organization serving approximately 2,000 patients increases revenue, users and patient census.
- Moderate pointMedian customer census at signing increased 4x from 2025 to 2026.
- Minor pointCode output exceeds 13 times first-quarter 2025 levels each quarter, without adding engineers.
- Minor pointCode output increased 37% in the third quarter of 2026 over the second quarter.
- Minor pointCustomer portfolio expansion adds healthcare services for rural Medicare and Medicaid populations.
Negative
- None.
Key Figures
- Patient census
- approximately 2,000 patients
- Healthcare organization covered by the new NurseMagic enterprise agreement
- Median customer census at signing
- 4x
- Company-reported increase from 2025 to 2026
Historical Context
-
NurseMagic won an approximately 2,700-patient-census enterprise customer, comparable to this new customer.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
emr medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Amesite announces its latest major enterprise win, increasing its revenue and deploying AI automations for another large healthcare organization in just days on its secure, AI-native infrastructure
DETROIT, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), an adaptive AI technology company and developer of the AI-native NurseMagic® documentation platform and LynkMagic™ enterprise solutions, today announced a new NurseMagic® enterprise agreement with a healthcare organization serving approximately 2,000 patients.
The contract ramps Amesite’s revenue, user base and patient census, and demonstrates another large company win for the Company’s portfolio. This announcement follows other substantial wins including a sales win under the minimum pricing model, a 2,700-census enterprise customer win in May 2026, a trading partner agreement enabling secure connectivity with an established homecare technology platform in March 2026, and the launch of its AI-native NurseMagic® EMR in December 2025. These milestones demonstrate continued execution of the Company's strategy to expand NurseMagic® adoption among larger healthcare organizations.
Amesite combines AI-native engineering with enterprise-scale execution, deploying sophisticated, production-ready AI systems in days rather than months. This capability enables Amesite to deliver enterprise-scale solutions with exceptional speed and efficiency, supporting attractive, high-margin subscription economics for mid-sized organizations while meeting the complex demands of large healthcare enterprises.
Dr. Ann Marie Sastry, Founder and CEO of Amesite, said, “We demonstrate production-ready AI systems during enterprise sales discussions and deploy customer-specific capabilities in days, not months. Our AI-native infrastructure enables us to meet complex healthcare requirements without lengthy development cycles or replacement of customers' existing systems. We are now converting these engineering advantages into larger enterprise agreements and recurring revenue opportunities.”
NurseMagic® automates work beyond transcription, transforming patient encounters into structured documentation and completing customer-specific electronic medical record (EMR) assessments, care plans, and forms. Its production capabilities include identifying missing information, generating targeted follow-up questions, and populating existing EMR workflows. NurseMagic® Record adds secure ambient and mobile recording, including offline capture with automatic synchronization when connectivity returns.
Together, these capabilities enable sophisticated enterprise automation within existing healthcare infrastructure. No rip and replace.
Kalie Wortinger, Head of Engineering at Amesite, said, “Our AI-native engineering infrastructure enables us to deliver increasingly sophisticated enterprise solutions at exceptional speed. We now ship more than 13 times as much code each quarter as we did in the first quarter of 2025, with another
Sai K. Nittala, Head of AI at Amesite, said, “Large healthcare organizations have established technology stacks, but many of the documentation tasks within those systems remain entrenched, tedious, and expensive to perform. Our agility allows us to fill those gaps quickly with AI capabilities tailored to different care settings and operational requirements. We deliver complex customer-specific solutions and sit on top of existing systems. This enables us to build value and ramp sales with large enterprises, without rebuilding our core platform.”
Madison Bush, Director of Corporate Operations at Amesite, said, "Our marketing results are measurable: median customer census at signing has increased 4x from 2025 to 2026, demonstrating our progress in attracting larger organizations and converting market intelligence into enterprise sales.”
Amesite has methodically expanded its customer base with increasingly large healthcare market segments, progressing from hospice and home care to skilled nursing, senior living, and enterprise workflows serving Medicare and Medicaid populations. Each expansion has built on the Company's existing AI infrastructure, positioning Amesite to serve increasingly complex organizations across the U.S. non-acute and post-acute healthcare markets.
This most recent contract win expands Amesite’s customer portfolio into healthcare services for rural Medicare and Medicaid populations. Across the U.S., this segment comprises 64.5 million rural Americans, including 17.8 million Medicaid enrollees and 11.8 million Medicare beneficiaries. Based on projected 2026 spending per enrollee, these populations represent an estimated
About Amesite Inc.
Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the
Built on proprietary AI trained on industry-specific data, NurseMagic® meets HIPAA regulations while improving accuracy and efficiency. The platform serves B2B and B2C users across 50 states and 21 countries, offering seamless integration into healthcare workflows and translations to over 50 languages.
Forward-Looking Statement
This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company and its business.
Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements.
Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its business are set forth in the Company's filings with the SEC.
Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.